5t4 oncofetal antigen expression in ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 5, Issue 4, 1995, Pages 269-274

  Wrigley, E ^a   McGown, A T ^b   Rennison, J ^a   Swindel, R ^a   Crowther, D ^a   Starzynska, T ^a   Stern, P L ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5T4 oncofetal antigen; Ovarian carcinoma; Survival

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN; IFOSFAMIDE; MELPHALAN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; COLORECTAL CARCINOMA; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; SECOND LOOK SURGERY; TUMOR DIFFERENTIATION;

EID: 0029025707     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1995.05040269.x     Document Type: Article

References (14)

1. Murphy D, Crowther D, Renninson J, et al. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for 6 cycles with half-dose chemotherapy given for twelve cycles. Ann Oncol 1993; 4: 377-83.
2. FIGO. Annual Report on the Results of Treatment in Gynaecological Cancer. Stockholm: International Federation of Gynaecologists and Obstetricians Cancer Committee, 1979; 17.
3. de Souza PL, Friedlander ML. Prognostic factors in ovarian cancer. Haematology/Oncology Clinics of North America, Vol. 6, No. 4, 1992.
4. Hole N, Stern PL. Isolation and characterisation of 5T4, a tumor associated antigen. Int J Cancer 1990; 45: 179-84.
5. Southall PJ, Boxer GM, Bagshaw KD, Hole N, Bromley M, Stern PL. Immunological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990; 61: 89-95.
6. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 1994; 69: 899-902.
7. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 1992; 66: 867-9.
8. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612.
9. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Smith PG. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
10. Nossal GJV. Minimal residual disease as the target for immunotherapy of cancer. Lancet 1994; 343: 1172-3.
11. Myers KA, Rahi-Saund V, Davison MD, Young JA, Cheater AJ, Stern PL. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. J Biol Chem 1994; 269: 9319-24.
12. Kaye SB, Lewis CR, Paul J, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian carcinomas. Lancet 1992; 340: 329-33.
13. McGuire WP, Hoskins WJ, Brady MF, Homesley MD, Clarke-Pearson DL. A phase III trial of dose intense versus standard dose cisplatin and cytoxan in advanced ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 226.
14. Riethmuller G, Schneider-Godicke E, Schlimak G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma. Lancet 1994; 343: 1177-83.